Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mohamed Och

Psychiatry Worcester, MA Medical Doctor

NPI 1629098496 CMS profile 119323

425 Lake Ave N Ste 101, Worcester, MA 01605

Open in the dashboard

General payments

$44,938

957 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mohamed Och of Worcester, MA is reported in the CMS Open Payments database as having received $44,938 across 957 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $675 15
2024 General $584 14
2023 General $4,568 184
2022 General $7,944 203
2021 General $10,946 283
2020 General $6,904 114
2019 General $13,317 144

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mohamed Och
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Mohamed Och were reported at $675. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Mohamed Och Psychiatry median Middle half National median
2019 $13,317 $184 $59–$605 $163
2020 $6,904 $119 $36–$372 $114
2021 $10,946 $143 $43–$576 $132
2022 $7,944 $153 $50–$590 $149
2023 $4,568 $170 $56–$651 $160
2024 $584 $179 $57–$673 $164
2025 $675 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Otsuka America Pharmaceutical, Inc. $14,210 152 payments
  2. AbbVie, Inc. $11,576 143 payments
  3. Allergan Inc. $5,407 85 payments
  4. Janssen Pharmaceuticals, Inc $1,902 60 payments
  5. Alkermes, Inc. $1,746 63 payments
  6. Neurocrine Biosciences, Inc. $1,376 56 payments
  7. Teva Pharmaceuticals USA, Inc. $1,258 46 payments
  8. Vanda Pharmaceuticals Inc. $1,150 45 payments
  9. ITI, Inc. $1,078 47 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $915 35 payments
  11. Other $4,321 225 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $23,624 20 payments
  2. Food and Beverage $19,851 914 payments
  3. Travel and Lodging $1,299 16 payments
  4. Education $165 7 payments
Products named General payments · program years 2019–2025
  1. REXULTI $13,531 106 payments
  2. VRAYLAR Neuroscience $11,484 139 payments
  3. VRAYLAR Neuroscience $5,500 89 payments
  4. SPRAVATO $1,371 44 payments
  5. ABILIFY MAINTENA $1,298 54 payments
  6. ARISTADA Cns $1,174 45 payments
  7. ARISTADA Cns $1,174 45 payments
  8. HETLIOZ $1,113 43 payments
  9. CAPLYTA $1,078 47 payments
  10. ARISTADA INITIO $955 35 payments
  11. Other $13,582 579 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

957 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record